机构：[1]Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX, United States,[2]Department of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Academy for Advanced Interdisciplinary Studies, Henan University, Kaifeng, China,[3]Cancer Center, Dalian Medical University, Dalian, China,[4]West China Hospital, Sichuan University, Chengdu, China四川大学华西医院
This editorial was supported by the Project of Higher
Interdisciplinary Research Institute of Henan University
(No. Y21008L).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2022]版：
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版：
大类|3 区医学
小类|3 区肿瘤学
第一作者：
第一作者机构：[1]Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX, United States,
通讯作者：
推荐引用方式(GB/T 7714)：
Zhang Jianying,Guo Xiangqian,Jin Bilian,et al.Editorial: Tumor-associated antigens and their autoantibodies, from discovering to clinical utilization[J].Frontiers in oncology.2022,12:970623.doi:10.3389/fonc.2022.970623.
APA：
Zhang Jianying,Guo Xiangqian,Jin Bilian&Zhu Qing.(2022).Editorial: Tumor-associated antigens and their autoantibodies, from discovering to clinical utilization.Frontiers in oncology,12,
MLA：
Zhang Jianying,et al."Editorial: Tumor-associated antigens and their autoantibodies, from discovering to clinical utilization".Frontiers in oncology 12.(2022):970623
